Literature DB >> 28180049

Invasive Aspergillosis of Anterior Skull Base in the Immunocompetent Host: Outcomes with a Combined Treatment Modality-An Institutional Experience.

Saurin R Shah1, Amit Keshri1, Simple Patadia1, Rungmei S K Marak2, Sanjay Behari1.   

Abstract

Objectives To study outcomes with voriconazole therapy in immunocompetent individuals following maximal safe endoscopic resection in invasive aspergillosis of the anterior skull base. Design Retrospective study of patients with chronic invasive aspergillosis including symptomatology, extent of disease, and response to voriconazole following maximal safe resection in immunocompetent individuals. Setting Tertiary care superspeciality referral center. Participants Ten consecutive patients of invasive aspergillosis of anterior skull base managed over a period of 2 years. Main Outcome Measures Symptom resolution with systemic voriconazole and radiologic evaluation following systemic antifungals as per predefined protocol. Conclusions Maximal safe resection via transnasal endoscopic route followed by systemic antifungals provides excellent outcomes in invasive skull base aspergillosis. Although liver and renal functions, besides visual acuity, need serial monitoring, voriconazole is well tolerated by our patients.

Entities:  

Keywords:  endoscopic resection; immunocompetent; invasive aspergillosis; itraconazole; skull base; voriconazole

Year:  2016        PMID: 28180049      PMCID: PMC5288116          DOI: 10.1055/s-0036-1585089

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  8 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 2.  Invasive sinus aspergillosis in apparently immunocompetent hosts.

Authors:  C J Clancy; M H Nguyen
Journal:  J Infect       Date:  1998-11       Impact factor: 6.072

3.  Chronic invasive aspergillosis in apparently immunocompetent hosts.

Authors:  M Karim; M Alam; A A Shah; R Ahmed; H Sheikh
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

4.  Diagnostic MR imaging features of craniocerebral Aspergillosis of sino-nasal origin in immunocompetent patients.

Authors:  A A Siddiqui; S H Bashir; A Ali Shah; Z Sajjad; N Ahmed; R Jooma; S Ather Enam
Journal:  Acta Neurochir (Wien)       Date:  2005-11-09       Impact factor: 2.216

5.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

6.  Sinonasal aspergillosis in immunocompetent Indian children: an eight-year experience.

Authors:  A K Gupta; S Ghosh; A K Gupta
Journal:  Mycoses       Date:  2003-12       Impact factor: 4.377

7.  Invasive aspergillosis in an immunocompetent host.

Authors:  Preeti Sethi; Ramandeep Saluja; Navin Jindal; Virender Singh
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

8.  Disseminated Aspergillosis due to Aspergillus niger in Immunocompetent Patient: A Case Report.

Authors:  Ulku Ergene; Zeynep Akcali; Demircan Ozbalci; Nalan Nese; Sebnem Senol
Journal:  Case Rep Infect Dis       Date:  2013-02-28
  8 in total
  1 in total

Review 1.  Fungal infections in pediatric neurosurgery.

Authors:  Adrian Caceres; Maria Luisa Avila; Marco Luis Herrera
Journal:  Childs Nerv Syst       Date:  2018-08-18       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.